ROBERT M. OGBURN, M.D.; ROBERT L. MYERS, M.D.; GEORGE E. BURDICK, M.D.
This content is PDF only. Please click on the PDF icon to access.
Dantrolene sodium, a hydantoin derivative that became commercially available in 1974, has been used to decrease skeletal muscle spasticity in patients with various disorders (1-3). The drug seems to exert its effect at a point distal to the neuromuscular junction by impairing release of calcium from the sarcoplasmic reticulum of the skeletal muscle cell (4). Reported adverse effects of dantrolene have included central nervous system effects (drowsiness, dizziness, weakness, light-headedness) and transient gastrointestinal upset with nausea, vomiting, or diarrhea. Adverse reactions have necessitated withdrawal of the drug in about 2.5% of cases (4).
Acute hepatitis associated with the administration of
OGBURN RM, MYERS RL, BURDICK GE. Hepatitis Associated with Dantrolene Sodium. Ann Intern Med. ;84:53–54. doi: 10.7326/0003-4819-84-1-53
Download citation file:
© 2019
Published: Ann Intern Med. 1976;84(1):53-54.
DOI: 10.7326/0003-4819-84-1-53
Gastroenterology/Hepatology, Liver Disease.
Results provided by: